Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
Add more filters










Publication year range
1.
J Leukoc Biol ; 106(5): 1161-1176, 2019 11.
Article in English | MEDLINE | ID: mdl-31313388

ABSTRACT

Ricin toxin is a plant-derived, ribosome-inactivating protein that is rapidly cleared from circulation by Kupffer cells (KCs) and liver sinusoidal endothelial cells (LSECs)-with fatal consequences. Rather than being inactivated, ricin evades normal degradative pathways and kills both KCs and LSECs with remarkable efficiency. Uptake of ricin by these 2 specialized cell types in the liver occurs by 2 parallel routes: a "lactose-sensitive" pathway mediated by ricin's galactose/N-acetylgalactosamine-specific lectin subunit (RTB), and a "mannose-sensitive" pathway mediated by the mannose receptor (MR; CD206) or other C-type lectins capable of recognizing the mannose-side chains displayed on ricin's A (RTA) and B subunits. In this report, we investigated the capacity of a collection of ricin-specific mouse MAb and camelid single-domain (VH H) antibodies to protect KCs and LSECs from ricin-induced killing. In the case of KCs, individual MAbs against RTA or RTB afforded near complete protection against ricin in ex vivo and in vivo challenge studies. In contrast, individual MAbs or VH Hs afforded little (<40%) or even no protection to LSECs against ricin-induced death. Complete protection of LSECs was only achieved with MAb or VH H cocktails, with the most effective mixtures targeting RTA and RTB simultaneously. Although the exact mechanisms of protection of LSECs remain unknown, evidence indicates that the Ab cocktails exert their effects on the mannose-sensitive uptake pathway without the need for Fcγ receptor involvement. In addition to advancing our understanding of how toxins and small immune complexes are processed by KCs and LSECs, our study has important implications for the development of Ab-based therapies designed to prevent or treat ricin exposure should the toxin be weaponized.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/immunology , Antigen-Antibody Complex/toxicity , Endothelial Cells/immunology , Kupffer Cells/immunology , Liver/immunology , Ricin/toxicity , Animals , Antigen-Antibody Complex/immunology , Cell Line , Endothelial Cells/pathology , Female , Kupffer Cells/pathology , Liver/pathology , Mice , Ricin/immunology
2.
Mol Immunol ; 85: 89-99, 2017 05.
Article in English | MEDLINE | ID: mdl-28214650

ABSTRACT

Increasing evidences indicate that 2-Methoxyestradiol (2ME2) plays an essential role in protecting against inflammatory responses. However, its effect on IgG immune complex (IC)-induced acute lung injury (ALI) remains enigmatic. In the study, by using i.p. administration of 2ME2, we evaluated its influence on IgG IC-induced pulmonary injury in mice. We found that during IgG IC-induced ALI, mice treated by 2ME2 displayed a substantial decrease in vascular permeability and neutrophil influx (represented by myeloperoxidase activity) when compared with their counterparts receiving vehicle treatment. Furthermore, 2ME2 treatment significantly decreased pro-inflammatory mediator production and inflammatory cell, especially neutrophil accumulation in bronchoalveolar lavage fluids (BALFs) upon IgG IC stimulation. In vitro, IgG IC-triggered inflammatory mediator production was markedly down-regulated by 2ME2 in macrophages. Moreover, we verified that the activation of the transcription factors, NF-κB and CCAAT/enhancer-binding protein (C/EBP) ß, were inhibited by 2ME2 in IgG IC-challenged macrophages. We demonstrated that alleviation of NF-κB-dependent transcription might be associated with reduced phosphorylation of NF-κB p65, and reduction of C/EBP activation was directly linked to its expression. In addition, we discovered that IgG IC-stimulated phosphorylation of both p38 MAPK and ERK1/2 was alleviated by 2ME2. These data indicated a novel strategy for blockade of IgG IC-induced inflammatory activities.


Subject(s)
Acute Lung Injury/metabolism , CCAAT-Enhancer-Binding Protein-beta/drug effects , Estradiol/analogs & derivatives , Macrophages, Alveolar/drug effects , NF-kappa B/drug effects , 2-Methoxyestradiol , Acute Lung Injury/immunology , Animals , Antigen-Antibody Complex/toxicity , Blotting, Western , CCAAT-Enhancer-Binding Protein-beta/immunology , CCAAT-Enhancer-Binding Protein-beta/metabolism , Disease Models, Animal , Estradiol/pharmacology , Immunoglobulin G/toxicity , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Male , Mice , Mice, Inbred C57BL , NF-kappa B/immunology , NF-kappa B/metabolism , Real-Time Polymerase Chain Reaction
3.
PLoS One ; 10(4): e0121637, 2015.
Article in English | MEDLINE | ID: mdl-25848767

ABSTRACT

Immune-complexes play an important role in the inflammatory diseases of the lung. Neutrophil activation mediates immune-complex (IC) deposition-induced acute lung injury (ALI). Components of gamma amino butyric acid (GABA) signaling, including GABA B receptor 2 (GABABR2), GAD65/67 and the GABA transporter, are present in the lungs and in the neutrophils. However, the role of pulmonary GABABR activation in the context of neutrophil-mediated ALI has not been determined. Thus, the objective of the current study was to determine whether administration of a GABABR agonist, baclofen would ameliorate or exacerbate ALI. We hypothesized that baclofen would regulate IC-induced ALI by preserving pulmonary GABABR expression. Rats were subjected to sham injury or IC-induced ALI and two hours later rats were treated intratracheally with saline or 1 mg/kg baclofen for 2 additional hours and sacrificed. ALI was assessed by vascular leakage, histology, TUNEL, and lung caspase-3 cleavage. ALI increased total protein, tumor necrosis factor α (TNF-α and interleukin-1 receptor associated protein (IL-1R AcP), in the bronchoalveolar lavage fluid (BALF). Moreover, ALI decreased lung GABABR2 expression, increased phospho-p38 MAPK, promoted IκB degradation and increased neutrophil influx in the lung. Administration of baclofen, after initiation of ALI, restored GABABR expression, which was inhibited in the presence of a GABABR antagonist, CGP52432. Baclofen administration activated pulmonary phospho-ERK and inhibited p38 MAPK phosphorylation and IκB degradation. Additionally, baclofen significantly inhibited pro-inflammatory TNF-α and IL-1ßAcP release and promoted BAL neutrophil apoptosis. Protective effects of baclofen treatment on ALI were possibly mediated by inhibition of TNF-α- and IL-1ß-mediated inflammatory signaling. Interestingly, GABABR2 expression was regulated in the type II pneumocytes in lung tissue sections from lung injured patients, further suggesting a physiological role for GABABR2 in the repair process of lung damage. GABABR2 agonists may play a potential therapeutic role in ALI.


Subject(s)
Acute Lung Injury/prevention & control , Antigen-Antibody Complex/toxicity , Baclofen/pharmacology , GABA-B Receptor Agonists/pharmacology , Inflammation Mediators/metabolism , Acute Lung Injury/etiology , Acute Lung Injury/metabolism , Animals , Apoptosis/drug effects , Blotting, Western , Bronchoalveolar Lavage Fluid/chemistry , Immunoenzyme Techniques , Lipopolysaccharides/pharmacology , Male , Rats , Rats, Long-Evans , Receptors, GABA-B/chemistry , Receptors, GABA-B/metabolism , Signal Transduction/drug effects , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
4.
Am J Physiol Lung Cell Mol Physiol ; 307(6): L435-48, 2014 Sep 15.
Article in English | MEDLINE | ID: mdl-25085625

ABSTRACT

Previous observations made by our laboratory indicate that Bruton's tyrosine kinase (Btk) may play an important role in the pathophysiology of local inflammation in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). We have shown that there is cross talk between FcγRIIa and TLR4 in alveolar neutrophils from patients with ALI/ARDS and that Btk mediates the molecular cooperation between these two receptors. To study the function of Btk in vivo we have developed a unique two-hit model of ALI: LPS/immune complex (IC)-induced ALI. Furthermore, we conjugated F(ab)2 fragments of anti-neutrophil antibodies (Ly6G1A8) with specific siRNA for Btk to silence Btk specifically in alveolar neutrophils. It should be stressed that we are the first group to perform noninvasive transfections of neutrophils, both in vitro and in vivo. Importantly, our present findings indicate that silencing Btk in alveolar neutrophils has a dramatic protective effect in mice with LPS/IC-induced ALI, and that Btk regulates neutrophil survival and clearance of apoptotic neutrophils in this model. In conclusion, we put forward a hypothesis that Btk-targeted neutrophil specific therapy is a valid goal of research geared toward restoring homeostasis in lungs of patients with ALI/ARDS.


Subject(s)
Acute Lung Injury/chemically induced , Acute Lung Injury/enzymology , Antigen-Antibody Complex/toxicity , Gene Silencing , Lipopolysaccharides/toxicity , Neutrophils/enzymology , Protein-Tyrosine Kinases/metabolism , Pulmonary Alveoli/enzymology , Acute Lung Injury/genetics , Acute Lung Injury/pathology , Agammaglobulinaemia Tyrosine Kinase , Animals , Female , Humans , Male , Mice , Mice, Inbred BALB C , Neutrophils/pathology , Protein-Tyrosine Kinases/genetics , Pulmonary Alveoli/pathology , Receptors, IgG/genetics , Receptors, IgG/metabolism , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
5.
mBio ; 5(2): e00949-14, 2014 Mar 18.
Article in English | MEDLINE | ID: mdl-24643866

ABSTRACT

The pathogenesis of malaria, an insect-borne disease that takes millions of lives every year, is still not fully understood. Complement receptor 1 (CR1) has been described as a receptor for Plasmodium falciparum, which causes cerebral malaria in humans. We investigated the role of CR1 in an experimental model of cerebral malaria. Transgenic mice expressing human CR1 (hCR1(+)) on erythrocytes were infected with Plasmodium berghei ANKA and developed cerebral malaria. No difference in survival was observed in hCR1(+) mice compared to wild-type mice following infection with P. berghei ANKA; however, hCR1 detection was significantly diminished on erythrocytes between days 7 and 10 postinfection. hCR1 levels returned to baseline by day 17 postinfection in surviving animals. Immunoblot assays revealed that total erythrocyte hCR1 levels were diminished, confirming that immune complexes in association with erythrocyte hCR1 were likely removed from erythrocytes in vivo by clearance following immune adherence. Decreases in hCR1 were completely dependent on C3 expression, as mice treated with cobra venom factor (which consumes and depletes C3) retained hCR1 on erythrocytes during C3 depletion through day 7; erythrocyte hCR1 decreases were observed only when C3 levels recovered on day 9. B-cell-deficient mice exhibit a marked increase in survival following infection with P. berghei ANKA, which suggests that immune complexes play a central role in the pathogenesis of experimental cerebral malaria. Together, our findings highlight the importance of complement and immune complexes in experimental cerebral malaria. IMPORTANCE Cerebral malaria is a deadly complication of infection with Plasmodium falciparum. Despite its high prevalence, relatively little is understood about its pathogenesis. We have determined that immune complexes are generated and deposited on erythrocytes specifically expressing human complement receptor 1 in a mouse model of cerebral malaria. We also provide evidence demonstrating the importance of immunoglobulins in the pathogenesis of cerebral malaria in mice. These findings may have important implications in human cerebral malaria.


Subject(s)
Antigen-Antibody Complex/immunology , Antigen-Antibody Complex/toxicity , B-Lymphocytes/immunology , Malaria, Cerebral/immunology , Malaria, Cerebral/pathology , Plasmodium berghei/immunology , Animals , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Receptors, Complement 3b/genetics , Receptors, Complement 3b/immunology , Survival Analysis
6.
J Immunol ; 188(5): 2437-44, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22287715

ABSTRACT

The molecular mechanisms of acute lung injury are incompletely understood. MicroRNAs (miRNAs) are crucial biological regulators that act by suppressing their target genes and are involved in a variety of pathophysiologic processes. miR-127 appears to be downregulated during lung injury. We set out to investigate the role of miR-127 in lung injury and inflammation. Expression of miR-127 significantly reduced cytokine release by macrophages. Looking into the mechanisms of regulation of inflammation by miR-127, we found that IgG FcγRI (CD64) was a target of miR-127, as evidenced by reduced CD64 protein expression in macrophages overexpressing miR-127. Furthermore, miR-127 significantly reduced the luciferase activity with a reporter construct containing the native 3' untranslated region of CD64. Importantly, we demonstrated that miR-127 attenuated lung inflammation in an IgG immune complex model in vivo. Collectively, these data show that miR-127 targets macrophage CD64 expression and promotes the reduction of lung inflammation. Understanding how miRNAs regulate lung inflammation may represent an attractive way to control inflammation induced by infectious or noninfectious lung injury.


Subject(s)
Acute Lung Injury/immunology , Acute Lung Injury/prevention & control , Gene Targeting/methods , Inflammation Mediators/physiology , MicroRNAs/physiology , Receptors, IgG/metabolism , Acute Lung Injury/pathology , Animals , Antigen-Antibody Complex/toxicity , Cell Line , Cytokines/antagonists & inhibitors , Cytokines/metabolism , Female , HEK293 Cells , Humans , Inflammation Mediators/metabolism , Lentivirus Infections/immunology , Lentivirus Infections/pathology , Lentivirus Infections/prevention & control , Macrophages/immunology , Macrophages/metabolism , Mice , Mice, Inbred C57BL , MicroRNAs/biosynthesis , MicroRNAs/genetics , Molecular Sequence Data , Pneumonia, Viral/immunology , Pneumonia, Viral/pathology , Pneumonia, Viral/prevention & control , Receptors, IgG/antagonists & inhibitors , Receptors, IgG/biosynthesis , Receptors, IgG/genetics , U937 Cells
7.
J Immunol ; 185(3): 1577-83, 2010 Aug 01.
Article in English | MEDLINE | ID: mdl-20585032

ABSTRACT

Anti-CD40L immunotherapy in systemic lupus erythematosus patients was associated with thromboembolism of unknown cause. We previously showed that monoclonal anti-CD40L immune complexes (ICs) activated platelets in vitro via the IgG receptor (FcgammaRIIa). In this study, we examined the prothrombotic effects of anti-CD40L ICs in vivo. Because mouse platelets lack FcgammaRIIa, we used FCGR2A transgenic mice. FCGR2A mice were injected i.v. with preformed ICs consisting of either anti-human CD40L mAb (M90) plus human CD40L, or a chimerized anti-mouse CD40L mAb (hMR1) plus mouse CD40L. ICs containing an aglycosylated form of hMR1, which does not bind FcgammaRIIa, were also injected. M90 IC caused shock and thrombocytopenia in FCGR2A but not in wild-type mice. Animals injected with hMR1 IC also experienced these effects, whereas those injected with aglycosylated-hMR1 IC did not, demonstrating that anti-CD40L IC-induced platelet activation in vivo is FcgammaRIIa-dependent. Sequential injections of individual IC components caused similar effects, suggesting that ICs were able to assemble in circulation. Analysis of IC-injected mice revealed pulmonary thrombi consisting of platelet aggregates and fibrin. Mice pretreated with a thrombin inhibitor became moderately thrombocytopenic in response to anti-CD40L ICs and had pulmonary platelet-thrombi devoid of fibrin. In conclusion, we have shown for the first time that anti-CD40L IC-induced thrombosis can be replicated in mice transgenic for FcgammaRIIa. This molecular mechanism may be important for understanding thrombosis associated with CD40L immunotherapy. The FCGR2A mouse model may also be useful for assessing the hemostatic safety of other therapeutic Abs.


Subject(s)
Antigen-Antibody Complex/physiology , Autoantibodies/toxicity , CD40 Ligand/immunology , Platelet Activation/immunology , Receptors, IgG/genetics , Thrombosis/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/biosynthesis , Antibodies, Monoclonal/toxicity , Antigen-Antibody Complex/administration & dosage , Antigen-Antibody Complex/toxicity , Autoantibodies/administration & dosage , Autoantibodies/therapeutic use , Humans , Hybridomas , Mice , Mice, Knockout , Mice, Transgenic , Platelet Activation/genetics , Receptors, IgG/deficiency , Receptors, IgG/physiology , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/physiology , Recombinant Fusion Proteins/toxicity , Thrombosis/blood
8.
Article in Chinese | MEDLINE | ID: mdl-16642209

ABSTRACT

BACKGROUND: To establish an immune complex induced rat liver fibrosis model by intraperitoneal injection of human serum albumin (HSA). METHODS: Male Wistar rats, weighting 110-120 g, were sensitized with HSA by subcutaneous injections at different sites for 4 shots at intervals of 14, 10 and 10 days. Ten days after the fourth injection, the peritoneal booster dose of HSA was administrated to rats twice weekly for 8 weeks with an initial dose of 5 mg, and progressive increase to 20 mg. Liver biopsy was performed at the beginning of HSA booster, 15, 30, 60 days after HSA booster, and 30, 60, 90, 120 days after discontinuation of HSA booster, respectively. Liver samples were examined for histological changes and liver hydroxyproline (HyP) was measured by biochemical method. Fibrosis serum markers hyaluronate acid (HA) and laminin (LN) were determined by RIA method. RESULTS: After intraperitoneal administration of HSA, the degree of liver pathological changes, the liver Hyp content and serum HA and LN increased (P<0.05). The longer the HSA administrated, the higher the liver pathological change degree (P<0.05) and the levels of liver Hyp and serum HA (P<0.01). After discontinuation of HSA, the levels of serum HA and liver Hyp decreased significantly (P<0.01) but were still significantly higher than those in the controls (P<0.01). The liver fibrosis formation rate was 100% and the fibrosis lasted more than 120 days. CONCLUSION: Intraperitoneal administration of HSA to make rat immune complex induced liver fibrosis model is convenient with high liver fibrosis formation rate and long fibrosis lasting time. The model may be used to evaluate the therapeutic effect of antifibrotic drugs.


Subject(s)
Antigen-Antibody Complex/toxicity , Liver Cirrhosis, Experimental/pathology , Serum Albumin/toxicity , Animals , Antigen-Antibody Complex/administration & dosage , Disease Models, Animal , Fibrosis , Humans , Hyaluronic Acid/metabolism , Hydroxyproline/metabolism , Injections, Intraperitoneal , Laminin/metabolism , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/metabolism , Male , Rats , Rats, Wistar , Serum Albumin/administration & dosage
9.
J Immunol ; 172(11): 6969-77, 2004 Jun 01.
Article in English | MEDLINE | ID: mdl-15153517

ABSTRACT

Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that modulate receptor signaling via tyrosine kinase pathways. We investigate the role of SOCS in renal disease, analyzing whether SOCS regulate IgG receptor (FcgammaR) signal pathways. In experimental models of immune complex (IC) glomerulonephritis, the renal expression of SOCS family genes, mainly SOCS-3, significantly increased, in parallel with proteinuria and renal lesions, and the proteins were localized in glomeruli and tubulointerstitium. Induction of nephritis in mice with a deficiency in the FcgammaR gamma-chain (gamma(-/-) mice) resulted in a decrease in the renal expression of SOCS-3 and SOCS-1. Moreover, blockade of FcgammaR by Fc fragment administration in rats with ongoing nephritis selectively inhibited SOCS-3 and SOCS-1, without affecting cytokine-inducible Src homology 2-containing protein and SOCS-2. In cultured human mesangial cells (MC) and monocytes, IC caused a rapid and transient induction of SOCS-3 expression. Similar kinetics was observed for SOCS-1, whereas SOCS-2 expression was very low. MC from gamma(-/-) mice failed to respond to IC activation, confirming the participation of FcgammaR. Interestingly, IC induced tyrosine phosphorylation of SOCS-3 and Tec tyrosine kinase, and both proteins coprecipitated in lysates from IC-stimulated MC, suggesting intracellular association. IC also activated STAT pathway in MC, which was suppressed by SOCS overexpression, mainly SOCS-3. In SOCS-3 knockdown studies, specific antisense oligonucleotides inhibited mesangial SOCS-3 expression, leading to an increase in the IC-induced STAT activation. Our results indicate that SOCS may play a regulatory role in FcgammaR signaling, and implicate SOCS as important modulators of cell activation during renal inflammation.


Subject(s)
Carrier Proteins/physiology , DNA-Binding Proteins/physiology , Glomerulonephritis/immunology , Intracellular Signaling Peptides and Proteins , Receptors, Fc/physiology , Repressor Proteins/physiology , Signal Transduction , Trans-Activators/physiology , Transcription Factors/physiology , Animals , Antigen-Antibody Complex/toxicity , Cells, Cultured , Female , Glomerulonephritis/etiology , Humans , Mast Cells/metabolism , Monocytes/metabolism , Phosphorylation , Protein-Tyrosine Kinases/physiology , Rats , Rats, Wistar , STAT1 Transcription Factor , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins , Tyrosine/metabolism
10.
Free Radic Biol Med ; 29(1): 8-16, 2000 Jul 01.
Article in English | MEDLINE | ID: mdl-10962200

ABSTRACT

Rats were subjected to acute lung injury by the intra-alveolar formation of IgG immune complexes of bovine serum albumin (BSA) and anti-BSA. In this model of injury, complement activation occurs and large numbers of neutrophils invade the interstitium and alveolar space. In the present study, animals were treated with intratracheal catalase concomitantly with anti-BSA or after a lag period of 5-120 min. Catalase treatment at time-zero or at 5 min post injury failed to prevent lung injury as indicated by permeability change, histological features, and neutrophil influx. However, treatment after a delay of 15-30 min (but not 120 min) afforded substantial protection. Consistent with past findings [19], lung injury was accompanied by an accumulation of matrix metalloproteinase 9 (MMP-9) in bronchoalveolar lavage (BAL) fluid. There was a strong correlation between inhibition of injury and reduction in MMP-9 levels. In vitro studies conducted in parallel revealed that unstimulated alveolar macrophages did not produce measurable MMP-9, while there was a large induction following exposure to the same immune complexes that initiated injury in vivo. MMP-2 was also slightly upregulated under the same conditions. Concomitant treatment with catalase greatly inhibited MMP-9 production by macrophages in response to immune complexes, but this treatment had little effect on basal production of either MMP-9 or MMP-2 by macrophage. The same concentration of catalase that suppressed MMP-9 elaboration also inhibited the production of tumor necrosis factor alpha. In contrast, when neutrophils were treated with catalase and then exposed to immune complexes, the antioxidant failed to prevent the release of either MMP-2 or MMP-9. Taken together, these findings demonstrate that antioxidant treatment interferes with elaboration of MMPs by alveolar macrophages. Protection against lung injury is correlated with reduction in MMP levels in the BAL fluid.


Subject(s)
Catalase/pharmacology , Lung/physiology , Macrophages, Alveolar/physiology , Matrix Metalloproteinase 9/metabolism , Neutrophils/physiology , Animals , Antigen-Antibody Complex/toxicity , Bronchoalveolar Lavage Fluid/cytology , Cattle , Immunoglobulin G/toxicity , Lung/drug effects , Lung/pathology , Male , Rats , Rats, Long-Evans , Serum Albumin, Bovine
11.
J Immunol ; 164(5): 2650-9, 2000 Mar 01.
Article in English | MEDLINE | ID: mdl-10679105

ABSTRACT

The role of the CC chemokines, macrophage inflammatory protein-1 beta (MIP-1 beta), monocyte chemotactic peptide-1 (MCP-1), and RANTES, in acute lung inflammatory injury induced by intrapulmonary deposition of IgG immune complexes injury in rats was determined. Rat MIP-1 beta, MCP-1, and RANTES were cloned, the proteins were expressed, and neutralizing Abs were developed. mRNA and protein expression for MIP-1 beta and MCP-1 were up-regulated during the inflammatory response, while mRNA and protein expression for RANTES were constitutive and unchanged during the inflammatory response. Treatment of rats with anti-MIP-1 beta Ab significantly decreased vascular permeability by 37% (p = 0.012), reduced neutrophil recruitment into lung by 65% (p = 0.047), and suppressed levels of TNF-alpha in bronchoalveolar lavage fluids by 61% (p = 0.008). Treatment of rats with anti-rat MCP-1 or anti-rat RANTES had no effect on the development of lung injury. In animals pretreated intratracheally with blocking Abs to MCP-1, RANTES, or MIP-1 beta, significant reductions in the bronchoalveolar lavage content of these chemokines occurred, suggesting that these Abs had reached their targets. Conversely, exogenously MIP-1 beta, but not RANTES or MCP-1, caused enhancement of the lung vascular leak. These data indicate that MIP-1 beta, but not MCP-1 or RANTES, plays an important role in intrapulmonary recruitment of neutrophils and development of lung injury in the model employed. The findings suggest that in chemokine-dependent inflammatory responses in lung CC chemokines do not necessarily demonstrate redundant function.


Subject(s)
Chemokine CCL2/physiology , Chemokine CCL5/physiology , Chemokines, CC/physiology , Lung/immunology , Lung/pathology , Macrophage Inflammatory Proteins/physiology , Acute Disease , Animals , Antibodies, Blocking/administration & dosage , Antigen-Antibody Complex/toxicity , Bronchoalveolar Lavage Fluid/immunology , Chemokine CCL2/administration & dosage , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL2/genetics , Chemokine CCL4 , Chemokine CCL5/administration & dosage , Chemokine CCL5/antagonists & inhibitors , Chemokine CCL5/genetics , Chemokines, CC/administration & dosage , Chemokines, CC/antagonists & inhibitors , Chemokines, CC/genetics , Chemotaxis, Leukocyte/immunology , Cloning, Molecular , Immune Sera/administration & dosage , Immunoglobulin G/toxicity , Intubation, Intratracheal , Lung/metabolism , Macrophage Inflammatory Proteins/administration & dosage , Macrophage Inflammatory Proteins/antagonists & inhibitors , Macrophage Inflammatory Proteins/genetics , Male , Pulmonary Alveoli/immunology , Pulmonary Alveoli/pathology , RNA, Messenger/biosynthesis , Rats , Rats, Long-Evans , Recombinant Proteins/biosynthesis , Recombinant Proteins/immunology
12.
J Immunol ; 163(5): 2909-15, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10453038

ABSTRACT

Macrolide antibiotics have unique immunomodulatory actions apart from antimicrobial properties. We studied the effects of macrolides on IgG immune complex (IgG-ICx)-induced lung injury in rats in vivo and in vitro. Intrapulmonary deposition of IgG-ICx produced a time-dependent increase in the concentration of NO in exhaled air. There were corresponding increases in the number of neutrophils accumulated into alveolar spaces, and lung wet-to-dry weight ratio. All of these changes were inhibited by pretreatment with erythromycin or josamycin, but not by amoxicillin or cephaclor. Incubation of cultured pulmonary alveolar macrophages caused up-regulation of NO production and expression of inducible NO synthase mRNA, an effect that was dose dependently inhibited by erythromycin, roxithromycin, or josamycin. The macrolides also reduced IgG-ICx-induced release of IL-1beta and TNF-alpha, but did not alter the release of NO induced by exogenously added IL-1beta and TNF-alpha. These results suggest that macrolide antibiotics specifically inhibit immune complex-induced lung injury presumably by inhibiting cytokine release and the resultant down-regulation of inducible NO synthase gene expression and NO production by rat pulmonary alveolar macrophages.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antigen-Antibody Complex/toxicity , Lung/immunology , Lung/pathology , Macrophages, Alveolar/metabolism , Nitric Oxide/physiology , Animals , Anti-Bacterial Agents/blood , Breath Tests , Cells, Cultured , Cytokines/metabolism , Erythromycin/blood , Erythromycin/therapeutic use , Gene Expression Regulation/drug effects , Lung/drug effects , Macrophages, Alveolar/drug effects , Male , Nitric Oxide/analysis , Nitric Oxide/metabolism , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Rats , Rats, Sprague-Dawley
13.
J Immunol ; 162(2): 1071-6, 1999 Jan 15.
Article in English | MEDLINE | ID: mdl-9916735

ABSTRACT

Using IgG immune complex deposition to trigger acute lung inflammation in rats, we have previously shown that exogenously administered IL-13 suppresses the acute inflammatory response. In the same model, expression of both mRNA and protein for IL-13 has now been detected. Treatment of rats with Ab to IL-13 accentuated the inflammatory response, with significant increases in lung vascular permeability and in the number of neutrophils in bronchoalveolar lavage fluids. In the presence of anti-IL-13, activation of the transcription factor, NF-kappaB, was significantly increased in lung. In addition, anti-IL-13 caused significant increases in bronchoalveolar lavage levels of TNF-alpha, macrophage inflammatory protein-2, and cytokine-inducible neutrophil chemoattractant but no changes in lung vascular ICAM-1. These data suggest that during lung inflammation endogenous IL-13 regulates NF-kappaB activation and related cytokine/chemokine generation, all of which determines the intensity of the lung inflammatory response.


Subject(s)
Alveolitis, Extrinsic Allergic/immunology , Alveolitis, Extrinsic Allergic/pathology , Interleukin-13/physiology , Acute Disease , Adjuvants, Immunologic/administration & dosage , Alveolitis, Extrinsic Allergic/etiology , Animals , Antigen-Antibody Complex/toxicity , Bronchoalveolar Lavage Fluid/immunology , Chemokines, CXC/metabolism , Immune Sera/administration & dosage , Immunoglobulin G/toxicity , Intercellular Adhesion Molecule-1/biosynthesis , Intercellular Adhesion Molecule-1/blood , Intercellular Adhesion Molecule-1/metabolism , Interleukin-13/biosynthesis , Interleukin-13/immunology , Intubation, Intratracheal , Lung/blood supply , Lung/metabolism , Male , NF-kappa B/metabolism , Rats , Rats, Long-Evans , Tumor Necrosis Factor-alpha/metabolism
15.
J Immunol ; 159(7): 3483-9, 1997 Oct 01.
Article in English | MEDLINE | ID: mdl-9317147

ABSTRACT

Using the IgG immune complex (BSA-anti-BSA) model of acute lung injury in rats, we have compared four intratracheally administered cytokines for their protective effects on parameters of injury (albumin leak and hemorrhage) and on neutrophil accumulation (lung content of myeloperoxidase). The descending rank order of protective effects was: IL-10 > or = IL-13 > IL-4 > > IL-12. In animals receiving an intratracheal instillation of 1.0 microg murine rIL-4, IL-10, IL-12 or IL-13, the levels of TNF-alpha in bronchoalveolar (BAL) fluids after intrapulmonary deposition of IgG immune complexes were reduced by 98, 98, 34, and 97%, respectively, implying a corresponding reduction in up-regulation of lung vascular intercellular adhesion molecule-1. The unexpected findings with IL-12 were further evaluated. In spite of reduced BAL levels of TNF-alpha in IL-12-treated animals, BAL levels of IFN-gamma were elevated sixfold, indicative of the expected biologic response to IL-12. Alveolar macrophages obtained from the same animals showed a 68% reduction in formation in vitro of NO2-/NO3-. When rats undergoing intrapulmonary deposition of IgG immune complexes were treated either i.v. or intratracheally with blocking Ab to murine IL-12, there were significant increases in lung permeability and myeloperoxidase values, suggesting that in this model intrinsic IL-12 functions in a regulatory manner. In homogenates of injured lungs, this Ab detected heterodimeric complex, consistent with rat IL-12. These data confirm the ability of certain cytokines to suppress in vivo lung inflammatory responses and underscore the unexpected anti-inflammatory activities of IL-12.


Subject(s)
Antigen-Antibody Complex/toxicity , Immunoglobulin G/toxicity , Interleukin-12/physiology , Interleukins/therapeutic use , Lung/immunology , Lung/pathology , Animals , Bronchoalveolar Lavage Fluid/immunology , Disease Models, Animal , Interleukin-10/therapeutic use , Interleukin-12/metabolism , Interleukin-12/therapeutic use , Interleukin-13/therapeutic use , Interleukin-4/therapeutic use , Lung/enzymology , Macrophages/metabolism , Male , Nitrates/metabolism , Nitrites/metabolism , Peroxidase/antagonists & inhibitors , Rats , Rats, Inbred Strains , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism
16.
Am J Pathol ; 151(1): 193-203, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9212745

ABSTRACT

Interleukin-6 (IL-6) is a cytokine produced in response to a variety of inflammatory stimuli. Although IL-6 is often observed in increased amounts in acute respiratory distress syndrome, its role in the development of lung injury is unclear. The role of IL-6 was studied in the rat model of lung injury induced by the intra-alveolar deposition of IgG immune complexes. IL-6 induction, as determined by Northern blot analysis and bioactivity, was found as a function of time during the course of development of injury. Recombinant IL-6 instilled intratracheally at commencement of injury led to substantial reductions in lung vascular permeability, neutrophil accumulation, and levels of tumor necrosis factor (TNF)-alpha and macrophage inflammatory protein (MIP)-2 in bronchoalveolar lavage fluids. Conversely, blocking of intrinsic IL-6 by a neutralizing antibody resulted in increases in lung vascular permeability, neutrophil content, and TNF-alpha levels in bronchoalveolar lavage fluids. Rat alveolar macrophages stimulated in vitro with lipopolysaccharide in the presence of IL-6 showed a significant reduction in TNF-alpha expression. Together, these findings suggest that IL-6 acts as an intrinsic regulator of lung inflammatory injury after deposition of IgG immune complexes and that the protective effects of exogenously administered IL-6 may be in part linked to suppressed TNF-alpha production.


Subject(s)
Antigen-Antibody Complex/toxicity , Immune Complex Diseases/pathology , Immune Complex Diseases/therapy , Immunoglobulin G/toxicity , Interleukin-6/pharmacology , Lung/pathology , Animals , Bronchoalveolar Lavage Fluid/chemistry , Cell Separation , Immune Complex Diseases/etiology , Immune Sera/pharmacology , Interleukin-6/genetics , Interleukin-6/immunology , Lung/drug effects , Male , RNA, Messenger/biosynthesis , Rats , Rats, Inbred Strains , Tumor Necrosis Factor-alpha/biosynthesis
17.
Infect Immun ; 65(5): 1800-7, 1997 May.
Article in English | MEDLINE | ID: mdl-9125564

ABSTRACT

Passive immunization with monoclonal antibodies (MAbs) specific for the major capsular polysaccharide of Cryptococcus neoformans alters the course of murine cryptococcosis. During studies of passive immunization for treatment of murine cryptococcosis, we noted the occurrence of an acute, lethal toxicity. Toxicity was characterized by scratching, lethargy, respiratory distress, collapse, and death within 20 to 60 min after injection of antibody. The toxic effect was observed only in mice with a cryptococcal infection and was reduced or absent in the early and late stages of disease. The clinical course and histopathology were consistent with those for shock. There was considerable variation between mouse strains in susceptibility to toxicity. Swiss Webster mice from the Charles River colony were most susceptible, followed by C3H/He, BALB/c, and C57BL/6 mice. DBA/2 mice and Swiss Webster mice from the Simonsen colony were resistant. Acute toxicity was mimicked by injection of preformed complexes of MAb and purified polysaccharide. The toxic effect was also produced by injection of MAbs into mice that were preloaded with polysaccharide. The toxic effect was not blocked by treatment of mice with chloropheniramine or anti-tumor necrosis factor alpha antibodies or by depletion of complement components via pretreatment with cobra venom factor. Toxicity was reduced by treatment of mice with high doses of epinephrine, dexamethasone, or chlorpromazine. Finally, the toxic effect was completely blocked by treatment of mice with the platelet-activating factor antagonist WEB 2170 BS or by pretreatment of mice with the liposome-encapsulated drug dichloromethylene diphosphonate, a procedure which depletes macrophages from the spleen and liver.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/toxicity , Cryptococcosis/immunology , Immunization, Passive/adverse effects , Polysaccharides/immunology , Animals , Antigen-Antibody Complex/immunology , Antigen-Antibody Complex/toxicity , Azepines/pharmacology , Chlorpheniramine/pharmacology , Chlorpromazine/pharmacology , Clodronic Acid/pharmacology , Complement System Proteins/metabolism , Dexamethasone/pharmacology , Elapid Venoms/pharmacology , Epinephrine/pharmacology , Female , Immunoglobulin Isotypes/immunology , Immunoglobulin Isotypes/physiology , Kidney/pathology , Liver/pathology , Lung/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred DBA , Polysaccharides/adverse effects , Polysaccharides/pharmacology , Shock/immunology , Shock/microbiology , Specific Pathogen-Free Organisms , Triazoles/pharmacology , Tumor Necrosis Factor-alpha/immunology
18.
J Immunol ; 158(7): 3439-48, 1997 Apr 01.
Article in English | MEDLINE | ID: mdl-9120305

ABSTRACT

The C-X-C chemokines of the IL-8 family possess potent chemotactic activity for neutrophils, but their in vivo role in inflammatory responses is not well understood. In the IgG immune complex-induced model of acute lung inflammatory injury in the rat we have evaluated the roles of two rat chemokines, macrophage inflammatory protein-2 (MIP-2) and cytokine-induced neutrophil chemoattractant (CINC). Both mRNA and protein for MIP-2 and CINC appeared in a time-dependent manner after initiation of IgG immune complex deposition in lung. There exists a 69% homology between the amino acid sequences for these proteins, and we found cross-reactivity between polyclonal Abs raised to these chemokines. By purifying the blocking Abs using double affinity methods (with Ag-immobilized beads), this cross-reactivity was removed. Individually, anti-MIP-2 and anti-CINC Ab significantly reduced lung injury (as measured by 125I-labeled albumin leakage from the pulmonary vasculature) and reduced neutrophil accumulation in the lung (as determined by myeloperoxidase (MPO content) and neutrophil counts in bronchoalveolar lavage (BAL) fluids); however, no change in TNF-alpha levels in BAL fluids was found. Chemotactic activity in BAL fluids collected 2 h after injury from animals undergoing immune complex deposition could be shown to be chiefly due to the combined contributions of MIP-2 (39%), CINC (28%), and C5a (21%). When either MIP-2 or CINC was blocked in vivo, up-regulation of Mac-1 expression on neutrophils obtained from BAL fluids was significantly reduced. These data suggest that, in the model studied, both MIP-2 and CINC contribute significantly to the influx of neutrophils and their activation.


Subject(s)
Antigen-Antibody Complex/toxicity , Chemokines, CXC , Chemokines/physiology , Chemotactic Factors/physiology , Growth Substances/physiology , Immunoglobulin G/toxicity , Intercellular Signaling Peptides and Proteins , Lung/immunology , Lung/pathology , Monokines/physiology , Animals , Antibodies/pharmacology , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Chemokine CXCL2 , Chemokines/genetics , Chemokines/immunology , Chemotactic Factors/genetics , Chemotactic Factors/immunology , Complement C5a/physiology , Cross Reactions , Growth Substances/genetics , Growth Substances/immunology , Leukocyte Count , Lung/enzymology , Lymphocyte Function-Associated Antigen-1/biosynthesis , Macrophage-1 Antigen/biosynthesis , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Male , Monokines/genetics , Monokines/immunology , Neutrophils/immunology , Neutrophils/metabolism , Peroxidase/metabolism , Rats , Rats, Inbred Strains , Tumor Necrosis Factor-alpha/metabolism
19.
Clin Exp Immunol ; 107(1): 83-8, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9010261

ABSTRACT

A low serum complement level is commonly found in patients with rheumatic diseases. We evaluated 170 patients with such diseases to determine their serum levels of CH50, C3 and C4 protein. Persistent hypocomplementaemia was found in 19 of those patients, particularly in those with systemic lupus erythematosus (SLE). Cold-dependent activation of complement (CDAC) was demonstrated in nine of the 19 (47.4%), and six of the nine patients demonstrated infection with HCV (66.7%). The nine patients that exhibited CDAC had nearly normal haemolytic complement activity when the sera were separated either at 37 degrees C or in EDTA-treated plasma. Conversely, it markedly decreased, even to the point of being immeasurable, when the sera were separated at 4-21 degrees C. No significant deficiency in C3 and C4 protein levels was found in these patients. Clinical parameters other than levels of anti-HCV antibody, transaminase, and RF were not influenced by CDAC. In an attempt to isolate the causal factor for CDAC, we isolated IgG fractions from the CDAC patients by using a protein G column, in which case precipitates were collected from the eluates. The precipitates were mixed with normal serum and incubated at 4-21 degrees C for 18 h. A decrease in the level of CH50 in normal serum was observed, which predominated (P < 0.001) when precipitates from HCV-infected patients were used. This indicated CDAC was possibly interrelated to the precipitates of such patients. This precipitate was proved to contain IgM besides IgG. It is therefore possible that an HCV-related IgG complex or an IgG-IgM RF complex may be formed at low temperature and be involved in activating the complement system in vitro.


Subject(s)
Antibodies, Viral/immunology , Antigen-Antibody Complex/immunology , Antigen-Antibody Complex/toxicity , Cold Temperature/adverse effects , Complement Activation/drug effects , Complement Activation/immunology , Hepacivirus/immunology , Rheumatic Diseases/immunology , Rheumatoid Factor/immunology , Rheumatoid Factor/toxicity , Adult , Aged , Aged, 80 and over , Antibodies, Viral/toxicity , Cryoglobulins/toxicity , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Middle Aged
20.
Clin Exp Immunol ; 106(3): 529-33, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8973623

ABSTRACT

Inflammatory bowel disease is associated with mucosal neutrophil recruitment and activatation, mediated in part by arachidonic acid metabolites. G-CSF attenuates the immune response to sepsis and ameliorates glycogen storage disease Ib-related colitis. These actions may be effected through the shedding of neutrophil adhesion molecules, or inhibition of proinflammatory mediator synthesis. Immune complex colitis was used to evaluate the effect of rhG-CSF on colonic mucosal inflammation, neutrophil recruitment and the generation of eicosanoids. Immune complex colitis was induced in White New Zealand rabbits. Animals were pretreated with rhG-CSF either 24 h before induction, or at induction, with dosages of 50 and 200 micrograms/kg. rhG-CSF caused a time- and dose-dependent neutrophilia in all animals. Pretreatment with rhG-CSF resulted in increased tissue myeloperoxidase levels, despite a histologically similar mucosal polymorphonuclear cell infiltrate between treated and control colitis groups. Leukotriene B4 (LTB4) and thromboxane B2 (TXB2) dialysis fluid levels were lower in treated animals, in particular in the groups receiving two doses (LTB4: both P < 0.01; TXB2: both P < 0.01. Prostaglandin E2 (PGE2) levels in dialysis fluid of the rhG-CSF-treated animals showed no difference from controls. In this model of experimental colitis, high-dose therapy with G-CSF resulted in a marked decrease of proinflammatory mediators, but mucosal generation of the protective PGE2 was preserved. These results suggest that prolonged high-dose therapy with G-CSF may have anti-inflammatory effects in colitis.


Subject(s)
Antigen-Antibody Complex/toxicity , Colitis/immunology , Colitis/therapy , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte Colony-Stimulating Factor/therapeutic use , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Animals , Colitis/pathology , Dialysis Solutions/metabolism , Eicosanoids/metabolism , Intestinal Mucosa/enzymology , Intestinal Mucosa/pathology , Leukocyte Count/drug effects , Male , Organ Specificity , Peroxidase/metabolism , Rabbits
SELECTION OF CITATIONS
SEARCH DETAIL
...